Can Recurrence and Progression be Predicted by HYAL-1 Expression in Primary T1 Bladder Cancer?

Abstract

Background: Molecular prognostic markers have been under investigation for the last decade and no validated marker to date has been proven to be used in daily clinical practice for urinary bladder cancers. The aim of the present study is to evaluate the significance of HYAL-1 expression in prediction of recurrence and progression in pT1 urothelial carcinomas. Materials and Methods: Eighty-nine urothelial carcinoma cases staged as T1 according to 2004 WHO classification were studied. Representative sections from every case were stained immunohistochemically for HYAL-1 and scored between 0 and +3, according to staining density, and graded as low and high for the scores 0-1 and 2-3, respectively. Results: Of the 89 pT1 bladder cancer patients, HYAL-1 expression was high in 92.1% (82 patients; 72 patients +3 and 10 patients +2) and low in 7.9% (only 7 patients; 6 patients +1 and 1 patient 0) of the cases. Of the 89 patients, 38 (42.7%) had recurrence and 22 (24.7%) showed progression. HYAL-1 staining did not show significant characteristics for tumor grade, accompanying CIS, multiplicity, tumor size, age and sex. HYAL-1 expression did not have any prognostic value in estimating recurrence or progression. Conclusions: HYAL-1 expression was found to be high, but did not have any prognostic importance in T1 bladder urothelial carcinomas.

Antitumor activity of sulfated hyaluronic acid fragments in pre-clinical models of bladder cancer

“…BCa is the first cancer model system in which HYAL-1 was found to be a molecular determinant of tumor growth, invasion, and angiogenesis and also as a diagnostic and prognostic marker [ 2 , 7 , 11 , 12 , 14 , 15 , 17 , 37 ]. The present study should significantly advance the field, as it shows targeting of HYAL-1 activity with specific inhibitors can be a potential therapeutic avenue for BCa patients.…”

Clinical Behavior of Bladder Urothelial Carcinoma in Young Patients: A Single Center Experience

“…Although several tumor markers such as p53, pRb, HYAL-1, and nestin were evaluated for the prognosis of non-muscle-invasive bladder urothelial carcinomas, they could not take a place in routine clinical use [ 22 – 24 ]. Even if microsatellite instability and p53 were found to be associated with clinical behavior and prognosis of younger patients, further comprehensive studies including larger patient cohorts are needed to clarify this relationship [ 20 , 25 ].…”

Current look at the most promising proteomic and glycomic biomarkers of bladder cancer

“…High expression of Hyal1 has been suggested to predict MIBC and recurrent BC and is associated with metastasis and decreased disease-specific survival (Kramer et al 2010 ). However, in pT1 BC, the expression of HYAL-1 did not have any prognostic importance (Mammadov et al 2014 ). In the recent meta-analysis, HYAL-1 demonstrated the highest PPV.…”